Merck KGaA FDA Approval of MAVENCLAD Conference Call Transcript
Dear ladies and gentlemen, welcome to the Merck investor and analyst conference call on FDA approves MAVENCLAD (cladribine) tablets as first and only short-course oral treatment for relapsing-remitting and active secondary progressive multiple sclerosis. (Operator Instructions) May I now hand you over to Constantin Fest, Head of Investor Relations, who will be -- lead you through this conference. Please go ahead, sir.
Many thanks, Anita. And a very warm welcome to this Merck conference call on the current news flow from our Healthcare business sector, the U.S. approval of MAVENCLAD. My name is Constantin Fest, Head of Investor Relations at Merck, and today, I'm joined in this call by Rehan Verjee, President of EMD Serono and Global Head of Innovative Medicine Franchises. Also joining us on this call are Luciano Rossetti, Global Head of Research and Development; as well as John Walsh, VP, Neurology, Immunology, U.S. Medical Affairs and Deputy CMO for North America.
During the next 30
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
